US61945A
(en)
|
|
1867-02-12 |
|
James maeshall |
US2229275A
(en)
|
1939-07-15 |
1941-01-21 |
M J B Company |
Key for cans
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
IL47062A
(en)
|
1975-04-10 |
1979-07-25 |
Yeda Res & Dev |
Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4665077A
(en)
|
1979-03-19 |
1987-05-12 |
The Upjohn Company |
Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
GB8705477D0
(en)
|
1987-03-09 |
1987-04-15 |
Carlton Med Prod |
Drug delivery systems
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
US4892538A
(en)
*
|
1987-11-17 |
1990-01-09 |
Brown University Research Foundation |
In vivo delivery of neurotransmitters by implanted, encapsulated cells
|
US5283187A
(en)
|
1987-11-17 |
1994-02-01 |
Brown University Research Foundation |
Cell culture-containing tubular capsule produced by co-extrusion
|
US5506126A
(en)
|
1988-02-25 |
1996-04-09 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
HUT53672A
(en)
|
1988-02-25 |
1990-11-28 |
Gen Hospital Corp |
Quick immunoselective cloning process
|
IL85746A
(en)
|
1988-03-15 |
1994-05-30 |
Yeda Res & Dev |
Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
|
US4861579A
(en)
|
1988-03-17 |
1989-08-29 |
American Cyanamid Company |
Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
|
FI891226A
(fi)
|
1988-04-28 |
1989-10-29 |
Univ Leland Stanford Junior |
Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
WO1990008187A1
(en)
|
1989-01-19 |
1990-07-26 |
Dana Farber Cancer Institute |
Soluble two domain cd2 protein
|
EP0463101B2
(en)
|
1989-03-21 |
2003-03-19 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
AU652540B2
(en)
|
1989-07-19 |
1994-09-01 |
Xoma Corporation |
T cell receptor peptides as therapeutics for autoimmune and malignant disease
|
US5013556A
(en)
*
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
WO1992000373A1
(en)
|
1990-06-29 |
1992-01-09 |
Biosource Genetics Corporation |
Melanin production by transformed microorganisms
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
EP0586505A1
(en)
|
1991-05-14 |
1994-03-16 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
EP0626012B1
(en)
|
1992-02-11 |
2003-07-09 |
Cell Genesys, Inc. |
Homogenotization of gene-targeting events
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
EP0633945B1
(en)
|
1992-04-03 |
1998-12-30 |
Genentech, Inc. |
ANTIBODIES TO ALPHAvBETA3 INTEGRIN
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
WO1993024640A2
(en)
|
1992-06-04 |
1993-12-09 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
DE69308573T2
(de)
|
1992-08-17 |
1997-08-07 |
Genentech Inc |
Bispezifische immunoadhesine
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
JP3095175B2
(ja)
|
1992-11-13 |
2000-10-03 |
アイデック ファーマシューティカルズ コーポレイション |
B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
|
ATE236987T1
(de)
|
1992-11-13 |
2003-04-15 |
Idec Pharma Corp |
Konsensus-kozak-sequenzen zur säugetier- exprimierung
|
US5648267A
(en)
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
US5417972A
(en)
|
1993-08-02 |
1995-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
|
US5595721A
(en)
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
DE69534530T2
(de)
|
1994-08-12 |
2006-07-06 |
Immunomedics, Inc. |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
US5910486A
(en)
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
PT2275119E
(pt)
|
1995-07-27 |
2013-11-21 |
Genentech Inc |
Formulação de proteína liofilizada isotónica estável
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US20010056066A1
(en)
|
1996-07-26 |
2001-12-27 |
Smithkline Beecham Corporation |
Method of treating immune cell mediated systemic diseases
|
US6024965A
(en)
|
1996-10-18 |
2000-02-15 |
Erasums University Rotterdam |
Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
|
ATE451391T1
(de)
|
1996-11-27 |
2009-12-15 |
Genentech Inc |
Affinitätsreinigung von polypeptid-proteinen auf einer matrix
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1998056418A1
(en)
|
1997-06-13 |
1998-12-17 |
Genentech, Inc. |
Stabilized antibody formulation
|
US6991790B1
(en)
*
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
US20040191256A1
(en)
|
1997-06-24 |
2004-09-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
AU8296098A
(en)
|
1997-07-08 |
1999-02-08 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
*
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
ES2261589T3
(es)
|
1998-05-06 |
2006-11-16 |
Genentech, Inc. |
Composicion de anticuerpos anti-her2.
|
GB9811969D0
(en)
|
1998-06-03 |
1998-07-29 |
Celltech Therapeutics Ltd |
Chemical compounds
|
NZ573838A
(en)
|
1998-08-11 |
2011-01-28 |
Biogen Idec Inc |
Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
|
GB9821061D0
(en)
|
1998-09-28 |
1998-11-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
EP1949912A3
(en)
|
1998-11-09 |
2008-08-13 |
Biogen Idec, Inc. |
Treatment of chronic lymphcytic leukemia (CLL) using chimeric anti-CD20 antibody
|
AU761516B2
(en)
|
1998-11-09 |
2003-06-05 |
Biogen Inc. |
Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants
|
GB9826174D0
(en)
|
1998-11-30 |
1999-01-20 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9828074D0
(en)
|
1998-12-18 |
1999-02-17 |
Glaxo Group Ltd |
Therapeutically useful compounds
|
EP1141024B1
(en)
|
1999-01-15 |
2018-08-08 |
Genentech, Inc. |
POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
US6596657B1
(en)
*
|
1999-02-17 |
2003-07-22 |
Poly-Med, Inc. |
Antimicrobial fabrics
|
EP1035172A3
(en)
|
1999-03-12 |
2002-11-27 |
Fuji Photo Film Co., Ltd. |
Azomethine compound and oily magenta ink
|
DK2270150T4
(da)
|
1999-04-09 |
2019-08-26 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
|
MXPA01011279A
(es)
|
1999-05-07 |
2002-07-02 |
Genentech Inc |
Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
|
JP4286483B2
(ja)
|
1999-06-09 |
2009-07-01 |
イムノメディクス, インコーポレイテッド |
B細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
DE19930748C2
(de)
|
1999-07-02 |
2001-05-17 |
Infineon Technologies Ag |
Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
|
MXPA02000419A
(es)
|
1999-07-12 |
2004-09-10 |
Genentech Inc |
Bloqueo de la respuesta inmune a un antigeno extrano utilizando un antagonista que se enlaza a cd20.
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
US6451284B1
(en)
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
CN100389825C
(zh)
|
1999-08-11 |
2008-05-28 |
拜奥根Idec公司 |
用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
|
WO2001013945A1
(en)
|
1999-08-23 |
2001-03-01 |
Biocrystal Ltd. |
Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
|
US6238302B1
(en)
*
|
1999-09-03 |
2001-05-29 |
Callaway Golf Company |
Golf club head with an insert having integral tabs
|
US20030039659A1
(en)
|
1999-09-24 |
2003-02-27 |
Mccormick Alison A. |
Self antigen vaccines for treating B cell lymphomas and other cancers
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Tatsuya Ogawa |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
US20020006404A1
(en)
|
1999-11-08 |
2002-01-17 |
Idec Pharmaceuticals Corporation |
Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
JP2003513937A
(ja)
|
1999-11-08 |
2003-04-15 |
アイデック・ファーマシューティカルズ・コーポレイション |
抗cd20抗体および/または化学療法薬および放射線療法と併用して抗cd40l抗体を使用するb細胞悪性疾患の処置
|
AU2001247219B2
(en)
|
2000-02-25 |
2007-01-04 |
Immunex Corporation |
Integrin antagonists
|
US20030185796A1
(en)
|
2000-03-24 |
2003-10-02 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
CA2404390A1
(en)
|
2000-03-24 |
2001-10-04 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
|
JP2004500412A
(ja)
|
2000-03-31 |
2004-01-08 |
アイデック ファーマスーティカルズ コーポレイション |
B細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗cd20の併用
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
DE60130910T2
(de)
|
2000-04-17 |
2008-07-10 |
Ucb Pharma, S.A. |
Enamin-derivate als zell-adhäsionsmoleküle
|
JP2003531178A
(ja)
|
2000-04-25 |
2003-10-21 |
アイデック ファーマスーティカルズ コーポレイション |
中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
|
AU2001268363B2
(en)
*
|
2000-06-20 |
2006-08-17 |
Biogen Idec Inc. |
Treatment of B cell associated diseases
|
SI1296714T1
(sl)
|
2000-06-22 |
2010-01-29 |
S For Entpr University Of Iowa |
Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
|
US6960597B2
(en)
|
2000-06-30 |
2005-11-01 |
Orth-Mcneil Pharmaceutical, Inc. |
Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
|
SG136804A1
(en)
|
2000-07-12 |
2007-11-29 |
Idec Pharma Corp |
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
|
DE60143984D1
(de)
|
2000-08-18 |
2011-03-17 |
Ajinomoto Kk |
Neue phenylalanin-derivate
|
US7332168B2
(en)
|
2000-08-22 |
2008-02-19 |
Micromet Ag |
Composition for the elimination of autoreactive B-cells
|
US20020058029A1
(en)
*
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
AU2001290303A1
(en)
|
2000-09-29 |
2002-04-15 |
Ajinomoto Co., Inc. |
Novel phenylalanine derivatives
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US20020128448A1
(en)
|
2000-10-20 |
2002-09-12 |
Idec Pharmaceuticals Corporation |
Variant IgG3 Rituxan and therapeutic use thereof
|
US6866866B1
(en)
*
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
AU2002256971B2
(en)
|
2000-12-28 |
2008-04-03 |
Altus Pharmaceuticals Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
EP1361892A4
(en)
|
2001-01-17 |
2004-10-13 |
Trubion Pharmaceuticals Inc |
BINDING DOMAIN FUSION PROTEIN Immunoglobulin
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2002240120B2
(en)
|
2001-01-29 |
2008-05-08 |
Biogen Idec Inc. |
Modified antibodies and methods of use
|
US7319139B2
(en)
|
2001-01-29 |
2008-01-15 |
Biogen Idec, Inc. |
TAG-72 specific CH2 domain deleted antibodies
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
CA2442801A1
(en)
|
2001-04-02 |
2002-10-10 |
Idec Pharmaceutical Corporation |
Recombinant antibodies coexpressed with gntiii
|
JP4679035B2
(ja)
|
2001-04-02 |
2011-04-27 |
ジェネンテック, インコーポレイテッド |
併用療法
|
WO2003061694A1
(en)
|
2001-05-10 |
2003-07-31 |
Seattle Genetics, Inc. |
Immunosuppression of the humoral immune response by anti-cd20 antibodies
|
WO2002102312A2
(en)
|
2001-06-14 |
2002-12-27 |
Intermune, Inc. |
Combination therapy of gamma-interferon and b cell specific antibodies
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
WO2003010135A1
(fr)
|
2001-07-26 |
2003-02-06 |
Ajinomoto Co., Inc. |
Nouveaux derives de l'acide phenylpropionique
|
KR20100018071A
(ko)
|
2001-08-03 |
2010-02-16 |
글리카트 바이오테크놀로지 아게 |
항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
|
DE60233744D1
(de)
|
2001-09-20 |
2009-10-29 |
Univ Texas |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
CN1210307C
(zh)
|
2001-11-16 |
2005-07-13 |
上海中信国健药业有限公司 |
抗cd20人源化单克隆抗体
|
AU2002362098A1
(en)
|
2001-12-07 |
2003-06-23 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
EP1454898A4
(en)
|
2001-12-13 |
2006-12-13 |
Ajinomoto Kk |
NEW PHENYL ALANIDE DERIVATIVES
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
KR101033196B1
(ko)
|
2002-02-14 |
2011-05-09 |
이뮤노메딕스, 인코오포레이티드 |
항-cd20 항체 및 그 융합 단백질 및 이들의 이용방법
|
WO2003070709A1
(fr)
|
2002-02-20 |
2003-08-28 |
Ajinomoto Co.,Inc. |
Nouveau derive de phenylalanine
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
EP2292247A3
(en)
*
|
2002-03-05 |
2011-10-05 |
Ramot at Tel Aviv University Ltd. |
Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
|
US7166441B2
(en)
|
2002-03-12 |
2007-01-23 |
Perseptive Biosystems Inc. |
Method and apparatus for the identification and quantification of biomolecules
|
US20030180292A1
(en)
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US7749753B2
(en)
|
2002-04-09 |
2010-07-06 |
Kyowa Hakko Kirin Co., Ltd |
Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
|
JPWO2003084569A1
(ja)
*
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
AU2003236018A1
(en)
*
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
US20050031613A1
(en)
*
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
CA2481657A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
WO2003089410A1
(fr)
|
2002-04-19 |
2003-10-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Derive de phenylalanine
|
US20030219818A1
(en)
|
2002-05-10 |
2003-11-27 |
Bohen Sean P. |
Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
|
CA2494104A1
(en)
|
2002-07-31 |
2004-04-22 |
Seattle Genetics, Inc. |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
PL216630B1
(pl)
|
2002-10-17 |
2014-04-30 |
Genmab As |
Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
AU2003297023A1
(en)
|
2002-12-16 |
2004-07-29 |
Genentech, Inc. |
Transgenic mice expressing human cd20
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
UA99933C2
(ru)
|
2003-04-09 |
2012-10-25 |
Дженентек, Инк. |
Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
|
KR101118460B1
(ko)
|
2003-04-09 |
2012-04-13 |
허큘레스 인코포레이티드 |
컨디셔닝 용도에서의 양이온성의 산화된 다당류
|
KR101351122B1
(ko)
|
2003-05-09 |
2014-01-14 |
듀크 유니버시티 |
Cd20-특이적 항체 및 이를 이용한 방법
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
JP2007536896A
(ja)
|
2003-06-05 |
2007-12-20 |
ジェネンテック・インコーポレーテッド |
Blysアンタゴニストとその用途
|
US20050163775A1
(en)
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
JP2007526450A
(ja)
*
|
2003-06-19 |
2007-09-13 |
ザイゴ コーポレーション |
平面ミラー干渉計測定システムにおけるビーム・ミスアライメントの幾何学的な影響に対する補償
|
WO2005011428A1
(en)
|
2003-07-25 |
2005-02-10 |
Bally Gaming International, Inc. |
Uniquely identifiable casino gaming chips
|
JP2007500844A
(ja)
|
2003-07-29 |
2007-01-18 |
ジェネンテック・インコーポレーテッド |
ヒト抗cd20抗体のアッセイとその用途
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
EP1660129A2
(en)
|
2003-08-29 |
2006-05-31 |
Genentech, Inc. |
Anti-cd20 therapy of ocular disorders
|
EP1688439A4
(en)
|
2003-10-08 |
2007-12-19 |
Kyowa Hakko Kogyo Kk |
HYBRID PROTEIN COMPOSITION
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
US20050186206A1
(en)
|
2003-12-19 |
2005-08-25 |
Genentech, Inc. |
Detection of CD20 in therapy of autoimmune diseases
|
CA2549237A1
(en)
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of cd20 in transplant rejection
|
UA86605C2
(ru)
|
2004-01-12 |
2009-05-12 |
Аплайд Молекьюлер Иволюшн, Инк. |
Антитело, которое содержит вариант исходного человеческого fс-участка
|
US7290012B2
(en)
|
2004-01-16 |
2007-10-30 |
International Business Machines Corporation |
Apparatus, system, and method for passing data between an extensible markup language document and a hierarchical database
|
JP2007532680A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
疾患の治療方法
|
AU2005241431A1
(en)
|
2004-04-16 |
2005-11-17 |
Genentech, Inc. |
Assay for antibodies
|
JP2007532681A
(ja)
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
ZA200608982B
(en)
|
2004-05-05 |
2008-06-25 |
Genentech Inc |
Preventing autoimmune disease by using an anti-CD20 antibody
|
WO2005114218A2
(en)
|
2004-05-15 |
2005-12-01 |
Genentech, Inc. |
Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
|
SV2006002131A
(es)
|
2004-06-04 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento de lupus
|
CN1993143A
(zh)
|
2004-06-04 |
2007-07-04 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
WO2006005477A1
(en)
|
2004-07-09 |
2006-01-19 |
Schering Ag |
Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
|
JP4501572B2
(ja)
*
|
2004-07-20 |
2010-07-14 |
富士ゼロックス株式会社 |
書類管理装置および書類管理システム
|
RU2007106722A
(ru)
|
2004-07-22 |
2008-08-27 |
Дженентек, Инк. (Us) |
Способ лечения синдрома шегрена
|
WO2006031370A2
(en)
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
CA2577823A1
(en)
|
2004-09-08 |
2006-03-16 |
Genentech, Inc. |
Methods of using death receptor ligands and cd20 antibodies
|
EP1802660A2
(en)
|
2004-09-08 |
2007-07-04 |
Genentech, Inc. |
Methods of using death receptor ligands and cd20 antibodies
|
CA2580271A1
(en)
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
GT200500283A
(es)
|
2004-10-08 |
2006-05-08 |
|
Inmunoterapia de desordenes autoinmunes
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
FR2879204B1
(fr)
*
|
2004-12-15 |
2007-02-16 |
Lab Francais Du Fractionnement |
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
|
EP1824885A1
(en)
|
2004-12-17 |
2007-08-29 |
Genentech, Inc. |
Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
|
EP2290088A1
(en)
|
2004-12-22 |
2011-03-02 |
Genentech, Inc. |
Methods for producing soluble multi-menbrane-spanning proteins
|
KR20070104593A
(ko)
|
2005-01-13 |
2007-10-26 |
제넨테크, 인크. |
치료 방법
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
TW200714289A
(en)
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
EP1865058B1
(en)
|
2005-03-31 |
2011-01-12 |
Biomedics Inc. |
Anti-cd-20 monoclonal antibody
|
AR053579A1
(es)
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
RU2007143302A
(ru)
|
2005-04-22 |
2009-05-27 |
Дженентек, Инк. (Us) |
Способ лечения деменции или болезни альцгеймера антителами к cd20
|
BRPI0612947A2
(pt)
|
2005-05-18 |
2010-12-07 |
Biogen Idec Inc |
método para o tratamento de uma condição fibrótica, método para tratar a fibrose pulmonar, método para tratar a fibrose hepática, método para tratar a fibrose renal, métodos para tratar uma doença fibrótica e método para prevenir uma doença fibrótica
|
BRPI0613259A2
(pt)
|
2005-05-20 |
2010-12-28 |
Genentech Inc |
método de tratamento de amostra biológica e kit de diagnóstico
|
JP2009508467A
(ja)
|
2005-05-24 |
2009-03-05 |
アベスタゲン リミテッド |
B細胞リンパ腫の治療のためのcd20に対するモノクローナル抗体を生成する方法
|
EP1891113A2
(en)
*
|
2005-06-02 |
2008-02-27 |
AstraZeneca AB |
Antibodies directed to cd20 and uses thereof
|
MX2007015107A
(es)
|
2005-06-03 |
2008-02-15 |
Genentech Inc |
Metodo para producir anticuerpos con funcion mejorada.
|
CN1290864C
(zh)
|
2005-07-11 |
2006-12-20 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗cd20嵌合抗体
|
WO2007014238A2
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals, Inc. |
Single dose use of cd20-specific binding molecules
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
ES2618543T3
(es)
|
2005-11-23 |
2017-06-21 |
Genentech, Inc. |
Métodos y composiciones relacionados con ensayos de linfocitos B
|
US20070136826A1
(en)
|
2005-12-02 |
2007-06-14 |
Biogen Idec Inc. |
Anti-mouse CD20 antibodies and uses thereof
|
US8524865B2
(en)
*
|
2006-05-30 |
2013-09-03 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
WO2008003319A1
(en)
|
2006-07-04 |
2008-01-10 |
Genmab A/S |
Cd20 binding molecules for the treatment of copd
|
WO2008030368A1
(en)
|
2006-09-08 |
2008-03-13 |
Tosoh Smd, Inc. |
Copper sputtering target with fine grain size and high electromigration resistance and methods of making the same
|
US20090204489A1
(en)
|
2007-04-02 |
2009-08-13 |
Genentech, Inc. |
Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
|
WO2008157282A1
(en)
|
2007-06-18 |
2008-12-24 |
Genentech, Inc. |
Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
|
JP5687057B2
(ja)
|
2007-07-09 |
2015-03-18 |
ジェネンテック, インコーポレイテッド |
ポリペプチドの組換え生産中におけるジスルフィド結合還元の防止
|
US8144978B2
(en)
|
2007-08-01 |
2012-03-27 |
Tandent Vision Science, Inc. |
System and method for identifying complex tokens in an image
|
CN101821292B
(zh)
|
2007-09-05 |
2014-03-26 |
霍夫曼-拉罗奇有限公司 |
Ⅰ型和ⅱ型抗-cd20抗体的组合疗法
|
GB0718684D0
(en)
|
2007-09-24 |
2007-10-31 |
Roche Products Ltd |
Treatment method
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
US20090110688A1
(en)
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
KR20140015166A
(ko)
|
2007-10-30 |
2014-02-06 |
제넨테크, 인크. |
양이온 교환 크로마토그래피에 의한 항체 정제
|
CN101945890A
(zh)
|
2007-12-21 |
2011-01-12 |
健泰科生物技术公司 |
抗cd20抗体的结晶
|
ES2511844T3
(es)
|
2007-12-21 |
2014-10-23 |
F. Hoffmann-La Roche Ag |
Formulación de anticuerpo
|
AU2008342956A1
(en)
|
2007-12-21 |
2009-07-09 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
MX2010009647A
(es)
|
2008-03-25 |
2010-09-28 |
Roche Glycart Ag |
Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano.
|
WO2009134738A1
(en)
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
CN102281902B
(zh)
|
2008-11-17 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
用于减少大分子在生理条件下聚集的方法和制剂
|
WO2010057107A1
(en)
|
2008-11-17 |
2010-05-20 |
Genentech, Inc. |
Method and formulation for reducing aggregation of a macromolecule under physiological conditions
|
JP5996429B2
(ja)
*
|
2009-09-03 |
2016-09-21 |
ジェネンテック, インコーポレイテッド |
関節リウマチの治療、診断及びモニターするための方法
|
KR20160061492A
(ko)
|
2014-11-21 |
2016-06-01 |
삼성디스플레이 주식회사 |
휴대용 먼지 센서 및 이를 이용한 휴대전화
|